 Torulopsis glabrata vaginitis clinical aspects susceptibility agents Torulopsis glabrata second Candida albicans frequency isolation vagina asymptomatic women patients yeast vaginitis patients vaginal isolates glabrata Torulopsis glabrata symptomatic vaginitis patients symptoms patients importance uncertain concomitant pathology Antifungal susceptibility testing glabrata strains patients minimal inhibitory concentrations MICs majority glabrata isolates sensitive range antimycotic drugs correlation vitro antifungal MICs response azole drug therapy Clinical success patients mycologic cure small number patients developed recurrent chronic Torulopsis vaginitis unresponsive conventional therapy Limited experience vaginal boric acid therapy value recalcitrant cases